MorphoSys Appoints Four R&D Experts to its Newly Formed Scientific Advisory Board
(Thomson Reuters ONE) -
MorphoSys AG /
MorphoSys Appoints Four R&D Experts to its Newly Formed Scientific Advisory
Board
. Processed and transmitted by Nasdaq Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) today
announced the appointment of four leading experts to its newly formed Scientific
Advisory Board (SAB). The SAB is set up to consult the Company with regard to
strategic options and future perspectives within its research and development
activities. The goal of the SAB is thus to further strengthen MorphoSys's
leadership position in discovery and clinical development of antibody and
peptide-based therapies for cancer, inflammation and other therapeutic fields of
high medical need.
The inaugural members of MorphoSys's Scientific Advisory Board are:
* Dr. Günther R. Adolf (former Vice President Pharmacology and Deputy Head of
Oncology Research at Boehringer Ingelheim, Vienna, Austria),
* Prof. Dr. Bruce D. Cheson (Professor of Medicine & Deputy Chief, Division of
Hematology and Oncology, Georgetown University Hospital, Washington D.C.,
USA),
* Dr. Sergio Quezada (Professorial Research Fellow and Group Leader, Immune
Regulation and Tumor Immunotherapy, University College London Cancer
Institute, London, UK), and
* Dr. Raymond W. Sweet (former Senior Director and Fellow, Biologics Research
at Janssen, J&J, Pennsylvania, USA).
"It is a great pleasure to welcome our new Scientific Advisory Board members to
MorphoSys," said Dr. Marlies Sproll, Chief Scientific Officer of MorphoSys AG.
"Their strong drug discovery and development expertise in therapeutic fields of
key interest to MorphoSys such as oncology, autoimmune and inflammatory diseases
will perfectly support our ongoing and future discovery and development
activities."
"We are excited to inaugurate a Scientific Advisory Board with highly
experienced experts, who will support us in growing and maturing our proprietary
pipeline of promising drug candidates," added Dr. Arndt Schottelius, Chief
Development Officer of MorphoSys AG. "Their scientific and clinical insight and
guidance will further help us to exploit the full potential of our portfolio."
About MorphoSys:
MorphoSys developed HuCAL, the most successful antibody library technology in
the pharmaceutical industry. By successfully applying this and other patented
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human healthcare.
Together with its pharmaceutical partners, MorphoSys has built a therapeutic
pipeline of more than 100 human antibody drug candidates for the treatment of
cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few. With
its ongoing commitment to new antibody technology and drug development,
MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is
listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates
about MorphoSys, visit http://www.morphosys.com.
HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®, RapMAT®, arYla®, Ylanthia®,
100 billion high potentials®, Slonomics®, Lanthio Pharma® and LanthioPep® are
registered trademarks of the MorphoSys Group.
This communication contains certain forward-looking statements concerning the
MorphoSys group of companies. The forward-looking statements contained herein
represent the judgment of MorphoSys as of the date of this release and involve
risks and uncertainties. Should actual conditions differ from the Company's
assumptions, actual results and actions may differ from those anticipated.
MorphoSys does not intend to update any of these forward-looking statements as
far as the wording of the relevant press release is concerned.
For more information, please contact:
MorphoSys AG
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR
Jochen Orlowski
Associate Director Corporate Communications & IR
Alexandra Goller
Senior Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-404
investors(at)morphosys.com
Media Release:
http://hugin.info/130295/R/2041087/761484.pdf
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: MorphoSys AG via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 12.09.2016 - 07:30 Uhr
Sprache: Deutsch
News-ID 494014
Anzahl Zeichen: 5105
contact information:
Town:
Martinsried / Munich
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 306 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"MorphoSys Appoints Four R&D Experts to its Newly Formed Scientific Advisory Board"
steht unter der journalistisch-redaktionellen Verantwortung von
MorphoSys AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
